Fludarabine was superior to chlorambucil in prolonging the time to disease progression both among the intermediate-risk patients (median, 23 vs. 16 months; P=0.02) ...

Chlorambucil oral tablet is a prescription medication used to treat certain types of cancer of the blood and lymph nodes. This drug doesn’t cure cancer, but it helps relieve its symptoms.

PATIENTS AND METHODS: Five hundred fifty-four previously untreated CLL patients with intermediate/high-risk Rai-stage disease were enrolled onto an intergroup protocol. Patients were randomized to ...

Chlorambucil was administered orally at a dose of 0.5 mg per kilogram of body weight on days 1 and 15 of each cycle (equivalent to the median dose in a previous trial showing noninferiority of ...

Cite this: Chlorambucil Is Still an Appropriate First-Line Therapy for Chronic Lymphocytic Leukaemia - Medscape - Oct 08, 2001. Introduction A Disease of Older Adults ...

Patients with chronic lymphocytic leukemia treated with chlorambucil and rituximab experienced better outcomes than those reported in prior studies of chlorambucil monotherapy, according to ...

Therapy consisted of chlorambucil 1 mg kg−1 given as 6 mg a day until the total dose was reached and lomustine 2 mg kg−1 given every 56 days (CL56). During this time all hormone therapy was ...

Clinical effectiveness. 3.1 The company identified 1 relevant randomised controlled trial to include in its submission. The CLL11 trial was a multicentre, open‑label, 3‑arm trial that compared ...

Chlorambucil is a cytotoxic chemotherapy drug, prescribed for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and lymphosarcoma. Chlorambucil Interaction with 48 drugs.

The results from COMPLEMENT 1, the randomised, open-label, parallel-arm, pivotal Phase III study evaluating the combination of ofatumumab and chlorambucil (N=221) versus chlorambucil alone (N=226 ...

Clinical effectiveness. 3.1 The company identified 1 relevant randomised controlled trial to include in its submission. The CLL11 trial was a multicentre, open‑label, 3‑arm trial that compared ...